hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
HVEC's entry into high-energy research accelerators began in 1949 with its 4 MV Cosmotron particle injector. By 1951, HVEC had begun producing its single-ended CN series that became the first mass-produced research accelerators. The CN design was based on a vertical accelerator at MIT designed by John Trump. It employed resistor grading in both column and tube structure, field-shaping column hoops, and high-pressure insulating gas mixtures of nitrogen and carbon dioxide. Operating in a single stage at terminal voltages up to 6.5 megavolts, the 26 CN models manufactured by HVEC reliable platforms for light-ion nuclear physics experiments. However, fundamental physics questions, particularly the structure of heavier nuclei, demanded higher particle energies than a single-stage Van de Graaff accelerator could reach.
=== Dosage forms === Prednisolone is supplied as oral liquid, oral suspension, oral syrup, oral tablet, and oral disintegrating tablet. It may be a generic medication or supplied as brands Flo-Pred (prednisolone acetate oral suspension), Millipred (oral tablets), Orapred (prednisolone sodium phosphate oral dissolving tablets), Pediapred (prednisolone sodium phosphate oral solution), Veripred 20, Prelone, Hydeltra-T.B.A., Hydeltrasol, Key-Pred, Cotolone, Predicort, Medicort, Predcor, Bubbli-Pred, Omnipred, P-Pred (prednisolone acetate ophthalmic suspension), Pred Mild, Pred Forte, and others.
26 June – Lecturers at Stirling University belonging to the Universities and Colleges Union announce a three-day strike beginning the following day amid claims their wages have been reduced by 50% for participating in a UK-wide marking boycott. 29 June – Lord Advocate Dorothy Bain launches a legal bid to overturn a 1997 ruling on evidence in rape cases that could allow more cases to be prosecuted.
Increased demand for iron, which the diet cannot accommodate. Increased loss of iron (usually through loss of blood). Nutritional deficiency. This can result due to a lack of dietary iron or consumption of foods that inhibit iron absorption. Absorption inhibition has been observed caused by phytates in bran, calcium from supplements or dairy products, and tannins from tea, although in all three of these studies the effect was small and the authors of the studies cited regarding bran and tea note that the effect will probably only have a noticeable impact when most iron is obtained from vegetable sources. Acid-reducing medications: Acid-reducing medications reduce the absorption of dietary iron. These medications are commonly used for gastritis, reflux disease, and ulcers. Proton pump inhibitors (PPIs), H2 antihistamines, and antacids will reduce iron metabolism. Damage to the intestinal lining. Examples of causes of this kind of damage include surgery involving the duodenum or diseases like Crohn's disease or celiac sprue which severely reduce the surface area available for absorption. Helicobacter pylori infections also reduce the availability of iron. Inflammation leading to hepcidin-induced restriction on iron release from enterocytes (see above). Is also a common occurrence in pregnant women, and in growing adolescents due to poor diets. Acute blood loss or acute liver cirrhosis creates a lack of transferrin therefore causing iron to be secreted from the body.
BBC News reports that Paul Powlesland has become the first juror to swear an oath on a river after doing so at Snaresbrook Crown Court. New powers under the Victims and Prisoners Act come into force that prevent prisoners convicted of the most serious offences in England and Wales from marrying while in custody. One of the first uses of the new legislation is to prevent convicted murderer Levi Bellfield from entering into a civil partnership with his girlfriend. Details are published of the autumn programme of COVID-19 vaccination, which will be broadly the same as 2023 with the vaccine offered to all adults aged 65 and over, as well as certain health and social care staff, older care home residents and people in clinical risk groups. 2024 riots: Rioting breaks out in Sunderland, where protestors clash with police outside a mosque. 3 August – The BBC removes a video promoting Children in Need 2018 from its website after it emerges the video features the suspect in the 2024 Southport stabbing. 4 August – Starmer condemns the ongoing "far-right thuggery" around the UK and says those involved "will regret it", as the number of people arrested in relation to the disorder exceeds 140. At least 10 police officers are injured at the Holiday Inn Express Hotel in Rotherham, with one left unconscious after a head injury, while others have broken bones. 5 August 2024 United Kingdom riots: Starmer holds an emergency COBRA meeting of ministers, civil servants, the police and intelligence officers in response to the rioting of recent days.
Sources: en.wikipedia.org
== Use in synthesis reactions == D-amino acid dehydrogenase has shown itself to be effective in the synthesis of branched-chain amino acids such as D-leucine, D-isoleucine, and D-valine. In the given study, researchers were successfully able to use D-amino acid dehydrogenase to create high amounts of these products from the starting material of 2-oxo acids, in the presence of ammonia. The conditions for this were variable, though the best results appeared at around 65 °C. Amino Acids obtained through these reactions resulted in a high enantioselectivity of >99% and high yields of >99%. Given the nature of this enzyme, it may be possible to use it in order to create non-branched D-amino acids as well as modified D-amino acids.
Crick was interested in two fundamental unsolved problems of biology: how molecules make the transition from the non-living to the living, and how the brain makes a conscious mind. He realised that his background made him more qualified for research on the first topic and the field of biophysics. In 1946 Crick read Erwin Schrödinger's book, What Is Life? and was influenced by it, and Linus Pauling, to switch from physics to biology. It was clear in theory that covalent bonds in biological molecules could provide the structural stability needed to hold genetic information in cells. It only remained as an exercise of experimental biology to discover exactly which molecule was the genetic molecule. In Crick's view, Charles Darwin's theory of evolution by natural selection, Gregor Mendel's genetics and knowledge of the molecular basis of genetics, when combined, revealed the secret of life. Crick had the very optimistic view that life would very soon be created in a test tube. However, some people (such as fellow researcher and colleague Esther Lederberg) thought that Crick was unduly optimistic. It was clear that some macromolecule such as a protein was likely to be the genetic molecule. However, it was well known that proteins are structural and functional macromolecules, some of which carry out enzymatic reactions of cells. In the 1940s, some evidence had been found pointing to another macromolecule, DNA, the other major component of chromosomes, as a candidate genetic molecule.
Half-Life: Echoes – Having a greater emphasis on survival horror than the base game, the player controls an unnamed scientist at the Black Mesa Research Facility surviving the Resonance Cascade and invasion by Xen and HECU forces. Point of View – A mod released on May 2, 2003 by the developers of Azure Sheep. The player character is a vortigaunt named Xonxt. The player can only use alien weaponry and has no armor. Medkits can't be used, instead Xen healing pools have to be used for restoring health. The Games Machine gave the mod a positive review. PC Zone gave the mod a rating of 76 out of 100 and called it "a refreshing alternative". Poke646 – Released in December 2001. Takes place after the events of Half-Life in Nation City. Features new weapons and textures. Named often one of the best single-player mods for Half-Life. Poke646: Vendetta – Released in December 2006. Sequel to Poke646. Received a positive review by PC Action. They Hunger – This is a single-player horror-based mod. It was released by Neil Manke's Black Widow Games in three episodes, the first in 1999, the second in 2000, and the final installment in 2001. All three were at one point bundled with PC Gamer magazine. USS Darkstar – A mod by Neil Manke, produced by PC Gamer and released on July 14, 1999. This mod follows a scientist on a deep-space scientific mission aboard an interstellar spacecraft. When an experiment goes awry, the player has to defend himself against aliens. The mod was first released on the PC Gamer website and was featured on the magazine's demo CD in August 1999.
Whereas the biological half-life of estradiol given by intravenous injection is about 0.5 to 2 hours, the biological half-life of oral estradiol has a range of 13 to 20 hours due to the large and long-lasting pool of estrogen conjugates that is formed during first-pass metabolism and that serves to continuously replenish circulating estradiol levels.
==== 17OHP subpathway ==== The first step of this pathway is the 5α-reduction of 17OHP to 5α-pregnan-17α-ol-3,20-dione (referred to as 17OHDHP or 17α-hydroxy-dihydroprogesterone). The reaction is catalyzed by SRD5A1. 17OHDHP is then converted to 5α-pregnane-3α,17α-diol-20-one (5α-Pdiol) via 3α-reduction by a 3α-hydroxysteroid dehydrogenase isozyme (AKR1C2 and AKR1C4) or HSD17B6, that also has 3α-reduction activity. The pathway then proceeds from 5α-Pdiol the same way as the pathway that starts from P4, i.e. 5α-Pdiol → AST → 3α-diol → DHT. The pathway can be summarized as: 17OHP → 17OHDHP → 5α-Pdiol → AST → 3α-diol → DHT.
Sources: en.wikipedia.org
Animals that commonly cause injury to plants include pests such as insects, mites, and nematodes. These variously bite or abrade plant parts such as leaves, stems, and roots, or as is common among the true bugs, pierce the plant's surface and suck plant juices. The resulting injuries may admit plant pathogens such as bacteria and fungi, which may extend the injury. Caterpillar larvae of agricultural pests such as cabbage white butterflies (Pieridae) can completely defoliate Brassica crops. Molluscs such as snails graze on plants including grasses and forbs, abrading them with their rasp-like radula; they can inflict substantial damage to crops. Grazing mammals including livestock such as cattle, too, bite off or break parts of plants including grasses, forbs, and forest trees, causing injury, and again, potentially admitting pathogens.
Freezing food preserves it from the time it is prepared to the time it is eaten. Since early times, farmers, fishermen, and trappers have preserved grains and produce in unheated buildings during the winter season. Freezing food slows decomposition by turning residual moisture into ice, inhibiting the growth of most bacterial species. In the food commodity industry, there are two processes: mechanical and cryogenic (or flash freezing). The freezing kinetics is important to preserve the food quality and texture. Quicker freezing generates smaller ice crystals and maintains cellular structure. Cryogenic freezing is the quickest freezing technology available due to the ultra low liquid nitrogen temperature −196 °C (−320 °F). Preserving food in domestic kitchens during modern times is achieved using household freezers. Accepted advice to householders was to freeze food on the day of purchase. An initiative by a supermarket group in 2012 (backed by the United Kingdom's Waste & Resources Action Programme) promotes the freezing of food "as soon as possible up to the product's 'use by' date". The Food Standards Agency was reported as supporting the change, provided the food had been stored correctly up to that time.
In 2008, Freeman was cast in the action-thriller Wanted, a loose adaptation of the comic book miniseries by Mark Millar and J. G. Jones. The plot revolves around Wesley Gibson (James McAvoy), a frustrated account manager who discovers that he is the son of a professional assassin and decides to join the Fraternity, a secret society of which Sloan (Freeman) is the leader. Principal photography took place in Chicago; co-star rapper Common remarked on the set atmosphere: "Freeman is a cool guy. He'd be walking around joking and singing and just dancing. You know, artists are free and I just felt the freedom in him." The film received generally favorable reviews; Peter Howell of Toronto Star thought it was original and one of Freeman's bolder performances to date. Freeman narrated The Love Guru (2008), before appearing in The Dark Knight (2008), the second installment of Christopher Nolan's Dark Knight Trilogy, in which he reprised his role as Lucius Fox. Freeman returned to Broadway in 2008 after an eighteen-year absence to co-star with Frances McDormand and Peter Gallagher in Clifford Odets' play, The Country Girl, directed by Mike Nichols. Freeman continued to accept roles in a diverse range of genres. In 2009, Freeman starred opposite Antonio Banderas in the heist movie Thick as Thieves. Next, he collaborated with Christopher Walken and William H. Macy for the comedy The Maiden Heist. For some time, Freeman expressed a desire to do a film based on Nelson Mandela.
Philip Hampton, at that time chair of the Royal Bank of Scotland, became GSK chairman in September 2015. On 31 March 2017, Emma Walmsley became CEO. She is the first female CEO of the company. In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner Banaja KSA Holding Company. With respect to rare diseases, the company divested its portfolio of gene therapy drugs to Orchard Therapeutics in April 2018. In November 2018, Reuters reported that Unilever was in prime position to acquire GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in a sale that could generate around US$4 billion for the company. Nestlé and Coca-Cola have also been reported to be interested in the business unit as they look to strengthen their presence in India. On 3 December 2018, GSK announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$3.8 billion (£2.98 billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Indian operation, Hindustan Unilever Limited. Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in a number of tranches. The same day, the company also announced it would acquire oncology specialist, Tesaro, for US$5.1 billion. The deal will give GSK control of ovarian cancer treatment, Zejula - a member of the class of poly ADP ribose polymerase (PARP) inhibitors.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.